CompletedPhase 1NCT02216331
PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
Studying Tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Global Alliance for TB Drug Development
- Principal Investigator
- Scott Rasmussen, MDCelerion (MDS Pharma Services)
- Intervention
- TMC207(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 19-55 years · All sexes
- Timeline
- 2010 – 2010
Study locations (1)
- Celerion (MDS Pharma Services), Lincoln, Nebraska, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02216331 on ClinicalTrials.govOther trials for Tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07164742Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)Johns Hopkins University
- RECRUITINGNCT0707721318F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis PatientsChildren's Hospital Medical Center, Cincinnati
- RECRUITINGNCT07451899TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung DiseaseUniversitas Padjadjaran
- RECRUITINGNCT06845618Blood Tuberculosis DNA Levels to Monitor Tuberculosis TreatmentUniversity of Oxford
- ENROLLING BY INVITATIONNANCT06984887Evaluation of New TB Diagnostic Tests (NATs) in PakistanMercy Corps Pakistan
- RECRUITINGNCT07018076Candidate Clinical Correlate of Prognostic Outcome for TB StudyUniversity of California, San Francisco
- RECRUITINGNANCT07271225Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and VomitingIndonesia University
- RECRUITINGNCT06585358DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary TuberculosisKarolinska Institutet